Dicerna expects to continue collaborating with Novo's rivals after potential acquisition

CEO at Dicerna Douglas Fambrough is fully anticipating that the US-based biotech company will live up to the obligations it has made to other companies, even in the case that the recently announced takeover bid by Novo Nordisk is a success, he tells MedWatch.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Even if Novo Nordisk's takeover bid becomes a success, business will continue as usual when it comes to Dicerna's partnerships with Novo's rivals Eli Lilly and Boehringer Ingelheim, CEO at Dicerna Douglas Fambrough tells MedWatch.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs